Boya Biotech: The company’s 2025 semi-annual equity distribution implementation announcement
Securities code: 300294 Securities abbreviation: Boya Biotechnology Announcement number: 2025-068
China Resources Boya Biopharmaceutical Group Co., Ltd.
2025 Semi-annual Equity Distribution Implementation Announcement
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Special tips:
- The profit distribution plan implemented by the company this time is: based on the total number of shares of 504,248,738 shares, a cash dividend of 1.500000 yuan (including tax) will be distributed to all shareholders for every 10 shares. The total amount of the company's cash dividend = actual participating share capital × distribution ratio = 504,248,738 shares × 1.500000 yuan ÷ 10 shares = 75,637,310.70 yuan (tax included).
If the total number of shares entitled to profit distribution changes before the equity registration date when equity distribution is implemented, the total number of shares entitled to profit distribution will be adjusted based on the total number of shares entitled to profit distribution on the equity registration date when the distribution plan is implemented, and the total distribution amount will be adjusted based on the principle that the distribution ratio remains unchanged.
In this equity distribution plan, the cash dividend per share is converted based on the company’s total share capital = the actual total cash dividend this time/the company’s total share capital = 75,637,310.70/504,248,738 = 0.150000 yuan.
The ex-rights and dividend reference price after the implementation of this equity distribution = the closing price on the trading day before ex-rights and ex-dividends - the cash dividend ratio per share converted based on the company's total share capital = the closing price on the trading day before ex-rights and ex-dividends - 0.150000 yuan/share.
1. The general meeting of shareholders reviewed and approved the profit distribution and capital reserve conversion plan, etc.
The 2025 semi-annual equity distribution plan of China Resources Boya Biopharmaceutical Group Co., Ltd. (hereinafter referred to as the Company) has been reviewed and approved by the 2025 first extraordinary general meeting of shareholders held on September 12, 2025. The distribution plan is The proposal is: based on 504,248,738 shares, a cash dividend of 1.5 million yuan (tax included) will be distributed to all shareholders for every 10 shares, 0 bonus shares (tax included) will be distributed, and capital reserve funds will be used to transfer 0 shares to all shareholders for every 10 shares.
If the total number of shares entitled to profit distribution changes before the equity registration date for equity distribution, the total number of shares entitled to profit distribution will be adjusted based on the total number of shares entitled to profit distribution on the equity registration date when the distribution plan is implemented, and the total distribution amount will be adjusted based on the principle that the distribution ratio remains unchanged.
The equity distribution plan implemented this time is consistent with the distribution plan reviewed and approved by the company’s first extraordinary shareholders’ meeting in 2025.
This equity distribution occurred within two months before the shareholders’ meeting reviewed and approved the profit distribution plan.
2. The profit distribution and capital reserve conversion plan implemented this time
Distribution year: Half year of 2025
Distribution plan: Based on the company’s existing total share capital of 504,248,738 shares, RMB 1.500000 in cash will be distributed to all shareholders for every 10 shares (including tax; after tax deduction, Hong Kong market investors, QFII, RQFII, and individuals and securities investment funds holding shares through Shenzhen-Hong Kong Stock Connect, as well as individuals and securities investment funds holding pre-IPO restricted shares will receive RMB 1.350000 for every 10 shares; holders of post-IPO restricted shares, equity incentive restricted shares, and Personal dividend tax on restricted tradable shares is levied at a differentiated rate. The company does not withhold personal income tax for the time being. When an individual transfers the stock, the tax payable is calculated based on the holding period [Note]; the dividend tax involved in securities investment funds holding post-IPO restricted shares, equity incentive restricted shares and unrestricted tradable shares is levied at 10% on the portion of the fund shares held by Hong Kong investors, and a differentiated tax rate is levied on the portion of fund shares held by mainland investors).
[Note: According to the first-in, first-out principle, the holding period is calculated based on the investor's securities account. If the stock is held for less than 1 month (including 1 month), the back tax will be 0.300000 yuan per 10 shares; if the stock is held for more than 1 month to 1 year (including 1 year), the back tax will be 0.150000 yuan for every 10 shares; if the stock is held for more than 1 year, no back tax is required. 】
3. Dividend payment date
Equity registration date: September 25, 2025
Ex-rights and ex-dividend date: September 26, 2025
4. Dividend distribution objects
As of the afternoon of September 25, 2025, after the Shenzhen Stock Exchange closes, all shareholders of the company registered in the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. (hereinafter referred to as China Securities Clearing Co., Ltd. Shenzhen Branch).
5. Distribution method
The cash dividends distributed by the Company to A-share shareholders entrusted by China Securities Clearing Company Shenzhen Branch will be directly transferred to their capital accounts through the shareholder custody securities company (or other custody institution) on September 26, 2025.
The following cash dividends to A-share shareholders will be distributed by the company itself:
Serial number Shareholder account number Shareholder name
1 08*****880 China Resources Pharmaceutical Holdings Co., Ltd.
2 08*****685 China Resources Pharmaceutical Holdings Co., Ltd.
3 08*****026 China Resources Pharmaceutical Holdings Co., Ltd.
4 08374 Shenzhen Gaotejia Investment Group Co., Ltd. 5 08389 During the application period for the equity distribution business of Fuzhou Jiayi Investment Partnership (Limited Partnership) (application date: September 18, 2025 to registration date: September 25, 2025), if the cash dividends entrusted to be distributed by China Securities Clearing Company Shenzhen Branch are insufficient due to a decrease in the shares in the securities accounts of self-distributed shareholders, our company shall bear all legal responsibilities and consequences.
6. Consulting agencies
Consultation address: No. 333, Huiquan Road, High-tech Industrial Development Zone, Fuzhou City, Jiangxi Province
Consultation contacts: Peng Dongke, Zhang Yapei
Consultation hotline: 0794-8264398
7. Documents for reference
Resolution of the company’s first extraordinary shareholders’ meeting in 2025;
Resolution of the 15th meeting of the company’s eighth board of directors;
Documents related to dividends and dividends confirmed by China Securities Clearing Company Shenzhen Branch.
Announcement is hereby made.
Board of Directors of China Resources Boya Biopharmaceutical Group Co., Ltd.
September 19, 2025